TGHN – Interventions WG

Meeting coordination group

Attended: Oscar, Julio, Mathildah, Mariam, Nicole, Davide

Date: 04-08-2020 13:00 BST
Location: Zoom

**Aim of the WG:** To develop an open MM platform trial going to assess impact of various PH interventions can be added to any kind of biomedical research.

**Recap from last meetings given - by Mariam and Mathildah:**

Different WGs are involved in various researchers → DXS, Vaccines, pharmaceuticals. Research moving at a lightning speed. If the biomedical model of Research for Covid-19 is not done in a way that the SS Research is integrated we will end up with intervention that might not been taken up.

There are issues with awareness, trust, adherence, etc. Misconceptions about pharmaceutical interventions, around local gov, international bodies like WHO, reg bodies like FDA, scientific experts guiding gov. All kind of pharmaceutical and non-pharmaceutical interventions have been affected by this.

Any intervention Research (vaccines, dx, etc) needs SS. We can build an open protocol to assess KAP and the level of trust, to measure adherence to PHIs, and reasons for non-compliance, using a MM approach. Can be ‘add on’ to vaccines, investigational drug research or any other.

This will provide a holistic evidence to understand public behaviour. This can be correlated to outcome data (eg epidemiological). Which varies according to contexts. This will complete the evidence, providing a mechanism to correlate to relevant outcomes (no just assessing mortality in hospitalised) this will let us know in a comprehensive way what works and what does not. This will allow to make appropriate community strategies.

Now there is a need to be more specific on the study topic, more precise using the PICOs and Outcomes. Which tools would we use?

**Points of the study designed mentioned on past meetings:**

1. Design:
   a. observational if it was to assess something in place
   b. randomised / comparative if different approaches where being considered and the platform study allows for both.
2. Outcome measure
   a. Change in behaviour
   b. Level of trust
   c. Change in an epidemiological outcome
      i. infection rate / transmission.
3. Which tools we will use to assess these outcomes?
4. Ethical issues
a. ethics of letting people not comply to social distancing etc is questionable."

b. consent process to be ethical especially in the midst of all the misconceptions about clinical trials going on?”

5. Important to include the role of Community Engagement to enable trials

**Next step:**

Mariam suggests she starts writing a draft using the PICOS, Outcome tools, core Outcome measures. She will share that by tomorrow end of the day, so that we can all look and give feedback on the outline.